-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: The early use of rituximab (RTX) in refractory idiopathic inflammatory myopathy (IIM) has not been well studie.
Methods: Registration-based observational data from patients with IIM receiving rituximab from 2018 to 2021 were include.
Results: A total of 42 patients (F:M=29:13) were included, with an average age (standard deviation) of 35 (±15) year.
Most patients received rituximab for refractory myositis after a median (IQR) duration of 8 (4, 18) month.
Improvements in manual muscle test (MMT-8) scores, PGA (Physician's Global Assessment), PtGA (Patient's Global Assessment), median steroid dose compared to baseline after 6 and 12 months of RTX ( p<01 for all items.
Changes in MMT-8, PGA, and PtGA scores were significantly different for both RTX dose regimens at 6 and 12 months from baselin.
Three patients in the cohort developed severe lower respiratory tract infections requiring hospitalizatio.
CONCLUSIONS: In this registry-based cohort study of refractory IIM, rituximab improved IMACS core-group measures with steroid-preserving efficacy at 6 and 12 month.
Source:
Janardana R, Amin SN, Rajasekhar L, et a.